Sean Douglas Aronow

This inventor holds 17 USPTO granted patents and 8 published patent applications, plus 2 CIPO patents and 3 EPO patents. Top assignees: Array Biopharma Inc., Eli Lilly and Company, Petra Pharma Corporation. Active years: 2018-2026.

USPTO Granted Patents = 17 (Patent Applications = 8)

% Patents Active = 100.0

CIPO Patents = 2 (Patent Applications = 3)

EPO Patents = 3 (Patent Applications = 7)

Average Co-Inventor Count = 16.7

ph-index = 5

Forward Citations = 54(Granted Patents)

Company Filing History:

Eli Lilly and Company

patents

3 out of 4

Petra Pharma Corporation

patents

Years Active: 2018-2026

Loading Chart...

17 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12723053 - KRas inhibitors (2026-09-01),

2. 12691117 - KRAS inhibitors (2026-07-28),

3. 12600733 - KRAS inhibitors (2026-04-14),

4. 11998545 - Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors (2024-06-04),

5. 11878970 - Allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of disease (2024-01-23),

6. 11873295 - Allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of disease (2024-01-16),

7. 11649227 - Allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of disease (2023-05-16),

8. 11648243 - Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors (2023-05-16),

9. 10953005 - Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors (2021-03-23),

10. 10881652 - Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors (2021-01-05),

11. 10555944 - Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors (2020-02-11),

12. 10441581 - Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors (2019-10-15),

13. 10172851 - Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors (2019-01-08),

14. 10172845 - Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors (2019-01-08),

15. 10144734 - Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors (2018-12-04),

Title: The Innovative Contributions of Sean Douglas Aronow

Introduction

Sean Douglas Aronow is a prominent inventor based in Boulder, Colorado, known for his significant contributions to the field of pharmaceuticals. With a total of 14 patents to his name, Aronow has made strides in developing compounds that target critical pathways in disease treatment.

Latest Patents

Among his latest patents, Aronow has developed substituted pyrazolo[1,5-a]pyridine compounds that serve as RET kinase inhibitors. These compounds are designed to treat and prevent diseases associated with RET kinase, including various RET-associated disorders. Another notable patent involves allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K), which are useful in treating diseases linked to PI3K modulation. These innovations highlight Aronow's commitment to advancing medical science through targeted therapies.

Career Highlights

Throughout his career, Sean Douglas Aronow has worked with several notable companies, including Array Biopharma Inc. and Petra Pharma Corporation. His experience in these organizations has allowed him to collaborate on groundbreaking research and development projects that have the potential to impact patient care significantly.

Collaborations

Aronow has collaborated with esteemed colleagues such as Gabrielle R Kolakowski and Steven Wade Andrews. These partnerships have fostered an environment of innovation and creativity, leading to the development of new therapeutic solutions.

Conclusion

Sean Douglas Aronow's work exemplifies the spirit of innovation in the pharmaceutical industry. His patents and collaborations reflect a dedication to improving health outcomes through scientific advancement.